| Mycophenolic acid |
EU/1/96/005/006 |
CellCept, Powder for oral suspension, 110, g, Pack: 1 |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
271.82 |
54.36 |
326.18 |
6% |
15 |
286.82 |
57.36 |
344.18 |
18% |
30 |
316.82 |
63.36 |
380.18 |
|
КЦ-529/13.02.2009 |
02.03.2009 |
Неактивен |
1143 |
| Maraviroc |
EU/1/07/418/003 |
Celsentri, Film‐coated tablet, 150, mg, Pack: 60 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Pfizer Manufacturing Deutschland GmbH, Германия |
1131.96 |
226.39 |
1358.35 |
4% |
10 |
1141.96 |
228.39 |
1370.35 |
16% |
25 |
1166.96 |
233.39 |
1400.35 |
|
НСР-8328/26.02.2016 |
16.03.2016 |
Активен |
3472 |
| Maraviroc |
EU/1/07/418/008 |
Celsentri, Film‐coated tablet, 300, mg, Pack: 60 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Pfizer Manufacturing Deutschland GmbH, Германия |
1131.96 |
226.39 |
1358.35 |
4% |
10 |
1141.96 |
228.39 |
1370.35 |
16% |
25 |
1166.96 |
233.39 |
1400.35 |
|
НСР-8333/26.02.2016 |
16.03.2016 |
Активен |
3473 |
| Maraviroc |
EU/1/07/418/008 |
Celsentri, Film‐coated tablet, 300, mg, Pack: 60 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Pfizer Manufacturing Deutsch-land GmbH, Герма-ния |
1131.98 |
226.4 |
1358.38 |
4% |
10 |
1141.98 |
228.4 |
1370.38 |
16% |
25 |
1166.98 |
233.4 |
1400.38 |
|
НСР-5311/ 18.12.2014. |
01.01.2015 |
Неактивен |
3473 |
| Maraviroc |
EU/1/07/418/003 |
Celsentri, Film‐coated tablet, 150, mg, Pack: 60 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Pfizer Manufacturing Deutsch-land GmbH, Герма-ния |
1131.98 |
226.4 |
1358.38 |
4% |
10 |
1141.98 |
228.4 |
1370.38 |
16% |
25 |
1166.98 |
233.4 |
1400.38 |
|
НСР-5310/ 18.12.2014. |
01.01.2015 |
Неактивен |
3472 |
| Maraviroc |
EU/1/07/418/003 |
Celsentri, Film‐coated tablet, 150, mg, Pack: 60 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Pfizer Manufacturing Deutschland GmbH, Германия |
1218.36 |
243.67 |
1462.03 |
4% |
10 |
1228.36 |
245.67 |
1474.03 |
16% |
25 |
1253.36 |
250.67 |
1504.03 |
|
НСР-3354/29.04.2014 |
13.05.2014 |
Неактивен |
3472 |
| Maraviroc |
EU/1/07/418/008 |
Celsentri, Film‐coated tablet, 300, mg, Pack: 60 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Pfizer Manufacturing Deutschland GmbH, Германия |
1218.36 |
243.67 |
1462.03 |
4% |
10 |
1228.36 |
245.67 |
1474.03 |
16% |
25 |
1253.36 |
250.67 |
1504.03 |
|
НСР-3380/29.04.2014 |
13.05.2014 |
Неактивен |
3473 |
| Maraviroc |
EU/1/07/418/008 |
Celsentri, Film‐coated tablet, 300, mg, Pack: 60 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Pfizer Manufacturing Deutschland GmbH, Германия |
1244.14 |
248.83 |
1492.97 |
4% |
10 |
1254.14 |
250.83 |
1504.97 |
16% |
25 |
1279.14 |
255.83 |
1534.97 |
|
НСР-1090/02.09.2013 |
18.09.2013 |
Неактивен |
3473 |
| Maraviroc |
EU/1/07/418/003 |
Celsentri, Film‐coated tablet, 150, mg, Pack: 60 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Pfizer Manufacturing Deutschland GmbH, Германия |
1244.14 |
248.83 |
1492.97 |
4% |
10 |
1254.14 |
250.83 |
1504.97 |
16% |
25 |
1279.14 |
255.83 |
1534.97 |
|
НСР-1090/02.09.2013 |
18.09.2013 |
Неактивен |
3472 |
| Maraviroc |
EU/1/07/418/008 |
Celsentri, Film‐coated tablet, 300, mg, Pack: 60 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Pfizer Manufacturing Deutschland GmbH, Германия |
1312.73 |
262.55 |
1575.28 |
4% |
10 |
1322.73 |
264.55 |
1587.28 |
16% |
25 |
1347.73 |
269.55 |
1617.28 |
промяна на обстоятелства решение КЦPP-2852/20.03.2013 |
КЦРР-2030/21.01.2013 |
03.04.2013 |
Неактивен |
3473 |
| Maraviroc |
EU/1/07/418/003 |
Celsentri, Film‐coated tablet, 150, mg, Pack: 60 |
Viiv Healthcare UK Ltd.,, Обединено Кралство |
Pfizer Manufacturing Deutschland GmbH, Германия |
1312.73 |
262.55 |
1575.28 |
4% |
10 |
1322.73 |
264.55 |
1587.28 |
16% |
25 |
1347.73 |
269.55 |
1617.28 |
промяна на обстоятелства решение КЦPP-2851/20.03.2013 |
КЦРР-2030/21.01.2013 |
03.04.2013 |
Неактивен |
3472 |
| Maraviroc |
EU/1/07/418/008 |
Celsentri, Film‐coated tablet, 300, mg, Pack: 60 |
Pfizer Limited, Обединено Кралство |
Gödecke GmbH (a pharma plant of Pfizer GmbH), Германия |
1525.55 |
305.11 |
1830.66 |
4% |
10 |
1535.55 |
307.11 |
1842.66 |
16% |
25 |
1560.55 |
312.11 |
1872.66 |
|
КЦ-856/12.05.2009 |
29.05.2009 |
Неактивен |
3473 |
| Maraviroc |
EU/1/07/418/003 |
Celsentri, Film‐coated tablet, 150, mg, Pack: 60 |
Pfizer Limited, Обединено Кралство |
Gödecke GmbH (a pharma plant of Pfizer GmbH), Германия |
1525.55 |
305.11 |
1830.66 |
4% |
10 |
1535.55 |
307.11 |
1842.66 |
16% |
25 |
1560.55 |
312.11 |
1872.66 |
|
КЦ-856/12.05.2009 |
29.05.2009 |
Неактивен |
3472 |
| Quetiapine |
II-5312/01.07.2009 |
CENTROQUEEN, Film‐coated tablet, 200, mg, Pack: 30 |
Чайкафарма Висококачествените лекарства АД, България |
"Чайкафарма Висококачествените Лекарства" АД, Пловдив, България |
71.48 |
14.3 |
85.78 |
4% |
2.86 |
74.34 |
14.87 |
89.21 |
16% |
11.44 |
85.78 |
17.16 |
102.94 |
|
КЦ-1111/09.09.2009 |
24.09.2009 |
Активен |
819 |
| Quetiapine |
II-5311/01.07.2009 |
CENTROQUEEN, Film‐coated tablet, 100, mg, Pack: 30 |
Чайкафарма Висококачествените лекарства АД, България |
"Чайкафарма Висококачествените Лекарства" АД, Пловдив, България |
50.66 |
10.13 |
60.79 |
4% |
2.03 |
52.69 |
10.54 |
63.23 |
16% |
8.11 |
60.8 |
12.16 |
72.96 |
|
КЦ-1111/09.09.2009 |
24.09.2009 |
Активен |
818 |
| Protein C |
EU/1/01/190/002 |
Ceprotin-1000 IU, Powder and solvent for solution for injection, 1000, IU, Pack: 100 mg/ml- 10 ml -1 vial powder + 1 vial solvent |
Baxter AG, Австрия |
Baxter AG – Industriestrasse 67 A-1221, Vienna, Austria |
2815.95 |
563.19 |
3379.14 |
4% |
10 |
2825.95 |
565.19 |
3391.14 |
16% |
25 |
2850.95 |
570.19 |
3421.14 |
Цената се заличава с решение НСР-5437/16.01.2015 ( в сила от 16.02.2015) |
КЦРР-1707/27.11.2012 |
14.12.2012 |
Заличен |
1466 |
| Protein C |
EU/1/01/190/001 |
Ceprotin-500 IU, Powder and solvent for solution for injection, 500, IU, Pack: 100 mg/ml- 5 ml -1 vial powder + 1 vial solvent |
Baxter AG, Австрия |
Baxter AG – Industriestrasse 67 A-1221, Vienna, Austria |
1407.55 |
281.51 |
1689.06 |
4% |
10 |
1417.55 |
283.51 |
1701.06 |
16% |
25 |
1442.55 |
288.51 |
1731.06 |
Цената се заличава с решение НСР-5437/16.01.2015 ( в сила от 16.02.2015) |
КЦРР-1707/27.11.2012 |
14.12.2012 |
Заличен |
1465 |
| Technetium [99mTc] exametazine |
II-15029/27.11.2006 |
Ceretec, Kit for radiopharmaceutical preparation, 0,5mg, -, Pack: 5 |
GE Healthcare Ltd, Обединено Кралство |
GE Healthcare Limited |
975.96 |
195.19 |
1171.15 |
4% |
10 |
985.96 |
197.19 |
1183.15 |
16% |
25 |
1010.96 |
202.19 |
1213.15 |
|
КЦ-823/15.04.2009 |
30.04.2009 |
Активен |
712 |
| Imiglucerase |
EU/1/97/053/003 |
Cerezyme, Powder for concentrate for solution for infusion, 400, U, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd., United Kingdom |
2488.3 |
497.66 |
2985.96 |
4% |
10 |
2498.3 |
499.66 |
2997.96 |
16% |
25 |
2523.3 |
504.66 |
3027.96 |
Протокол №116/14.05.2015 |
НСР-5971/01.04.2015. |
16.04.2015 |
Неактивен |
3748 |
| Imiglucerase |
EU/1/97/053/003 |
Cerezyme, Powder for concentrate for solution for infusion, 400, U, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd., United Kingdom |
2524 |
504.8 |
3028.8 |
4% |
10 |
2534 |
506.8 |
3040.8 |
16% |
25 |
2559 |
511.8 |
3070.8 |
|
НСР-4295/05.08.2014 |
20.08.2014 |
Неактивен |
3748 |
| Imiglucerase |
EU/1/97/053/003 |
Cerezyme, Powder for concentrate for solution for infusion, 400, U, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd., United Kingdom |
2572.74 |
514.55 |
3087.29 |
4% |
10 |
2582.74 |
516.55 |
3099.29 |
16% |
25 |
2607.74 |
521.55 |
3129.29 |
|
НСР-1612/01.11.2013 |
26.12.2013 |
Неактивен |
3748 |
| Imiglucerase |
EU/1/97/053/003 |
Cerezyme, Powder for concentrate for solution for infusion, 400, U, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd., United Kingdom |
2625.06 |
525.01 |
3150.07 |
4% |
10 |
2635.06 |
527.01 |
3162.07 |
16% |
25 |
2660.06 |
532.01 |
3192.07 |
|
КЦ-1351/01.02.2010 |
15.02.2010 |
Неактивен |
3748 |
| Imiglucerase |
EU/1/97/053/001 |
Cerezyme, -, 200, U, Pack: 1 |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd., United Kingdom |
1277.31 |
255.46 |
1532.77 |
4% |
10 |
1287.31 |
257.46 |
1544.77 |
16% |
25 |
1312.31 |
262.46 |
1574.77 |
Протокол №116/14.05.2015; цената е заличена с решение НСР-6132/29.04.2015 (в сила от 02.06.2015 ) |
КЦ-1351/01.02.2010 |
15.02.2010 |
Заличен |
891 |
| Imiglucerase |
EU/1/97/053/003 |
Cerezyme 400 U, Powder for concentrate for solution for infusion, 40U/ml - 10 ml, -, Pack: 1 vial |
Genzyme Europe B.V., Нидерландия |
Genzyme Ltd., 37 Hollands Road, Haverhill Suffolk CB9 8PU, Великобритания; Genzyme Ireland Ltd., IDA Industrial Park, Old Kilmeaden Road, Waterford, Ирландия |
2467.69 |
493.54 |
2961.23 |
4% |
10 |
2477.69 |
495.54 |
2973.23 |
16% |
25 |
2502.69 |
500.54 |
3003.23 |
промяна в обстоятелства НСР-8696/06.04.2016. |
НСР-7859/15.01.2016. |
02.02.2016 |
Активен |
3748 |
| Everolimus |
15807/29.12.2006 г. |
Certican, Tablet, 0.25, mg, Pack: 60 |
Novartis Pharma GmbH, Германия |
Novartis Pharma GmbH, Germany |
167.05 |
33.41 |
200.46 |
4% |
6.68 |
173.73 |
34.75 |
208.48 |
16% |
25 |
198.73 |
39.75 |
238.48 |
|
НСР-6787/23.07.2015 |
08.08.2015 |
Активен |
3401 |